Michael A Portman1, Nagib S Dahdah2, April Slee3, Aaron K Olson4, Nadine F Choueiter5, Brian D Soriano4, Sujatha Buddhe4, Carolyn A Altman6. 1. Seattle Children's Research Institute, School of Medicine, University of Washington, Seattle, Washington; michael.portman@seattlechildrens.org. 2. Sainte Justine University Hospital Center, University of Montreal, Montreal, Canada. 3. Axio Research, Seattle, Washington. 4. Seattle Children's Research Institute, School of Medicine, University of Washington, Seattle, Washington. 5. Montefiore Children's Hospital, Albert Einstein College of Medicine, Bronx, New York; and. 6. Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
Abstract
OBJECTIVES:Patients with Kawasaki disease can develop life-altering coronary arterial abnormalities, particularly in those resistant to intravenous immunoglobulin (IVIg) therapy. We tested the tumor necrosis factor α receptor antagonist etanercept for reducing both IVIg resistance and coronary artery (CA) disease progression. METHODS: In a double-blind multicenter trial, patients with Kawasaki disease received either etanercept (0.8 mg/kg; n = 100) or placebo (n = 101) subcutaneously starting immediately after IVIg infusion. IVIg resistance was the primary outcome with prespecified subgroup analyses according to age, sex, and race. Secondary outcomes included echocardiographic CA measures within subgroups defined by coronary dilation (z score >2.5) at baseline. We used generalized estimating equations to analyze z score change and a prespecified algorithm for change in absolute diameters. RESULTS:IVIg resistance occurred in 22% (placebo) and 13% (etanercept) of patients (P = .10). Etanercept reduced IVIg resistance in patients >1 year of age (P = .03). In the entire population, 46 (23%) had a coronary z score >2.5 at baseline. Etanercept reduced coronary z score change in those with and without baseline dilation (P = .04 and P = .001); no improvement occurred in the analogous placebo groups. Etanercept (n = 22) reduced dilation progression compared with placebo (n = 24) by algorithm in those with baseline dilation (P = .03). No difference in the safety profile occurred between etanercept and placebo. CONCLUSIONS:Etanercept showed no significant benefit in IVIg resistance in the entire population. However, preplanned analyses showed benefit in patients >1 year. Importantly, etanercept appeared to ameliorate CA dilation, particularly in patients with baseline abnormalities.
RCT Entities:
OBJECTIVES:Patients with Kawasaki disease can develop life-altering coronary arterial abnormalities, particularly in those resistant to intravenous immunoglobulin (IVIg) therapy. We tested the tumor necrosis factor α receptor antagonist etanercept for reducing both IVIg resistance and coronary artery (CA) disease progression. METHODS: In a double-blind multicenter trial, patients with Kawasaki disease received either etanercept (0.8 mg/kg; n = 100) or placebo (n = 101) subcutaneously starting immediately after IVIg infusion. IVIg resistance was the primary outcome with prespecified subgroup analyses according to age, sex, and race. Secondary outcomes included echocardiographic CA measures within subgroups defined by coronary dilation (z score >2.5) at baseline. We used generalized estimating equations to analyze z score change and a prespecified algorithm for change in absolute diameters. RESULTS: IVIg resistance occurred in 22% (placebo) and 13% (etanercept) of patients (P = .10). Etanercept reduced IVIg resistance in patients >1 year of age (P = .03). In the entire population, 46 (23%) had a coronary z score >2.5 at baseline. Etanercept reduced coronary z score change in those with and without baseline dilation (P = .04 and P = .001); no improvement occurred in the analogous placebo groups. Etanercept (n = 22) reduced dilation progression compared with placebo (n = 24) by algorithm in those with baseline dilation (P = .03). No difference in the safety profile occurred between etanercept and placebo. CONCLUSIONS: Etanercept showed no significant benefit in IVIg resistance in the entire population. However, preplanned analyses showed benefit in patients >1 year. Importantly, etanercept appeared to ameliorate CA dilation, particularly in patients with baseline abnormalities.
Authors: Samuel S Gidding; Bruce A Barton; Joanne A Dorgan; Sue Y S Kimm; Peter O Kwiterovich; Normal L Lasser; Alan M Robson; Victor J Stevens; Linda Van Horn; Denise G Simons-Morton Journal: Pediatrics Date: 2006-12 Impact factor: 7.124
Authors: Sadeep Shrestha; Howard W Wiener; Aaron K Olson; Jeffrey C Edberg; Neil E Bowles; Hitendra Patel; Michael A Portman Journal: J Allergy Clin Immunol Date: 2011-05-20 Impact factor: 10.793
Authors: Michael A Portman; April Slee; Aaron K Olson; Gordon Cohen; Tom Karl; Elizabeth Tong; Laura Hastings; Hitendra Patel; Olaf Reinhartz; Antonio R Mott; Richard Mainwaring; Justin Linam; Sara Danzi Journal: Circulation Date: 2010-09-14 Impact factor: 29.690
Authors: Robert J Moots; Ricardo M Xavier; Chi Chiu Mok; Mahboob U Rahman; Wen-Chan Tsai; Mustafa H Al-Maini; Karel Pavelka; Ehab Mahgoub; Sameer Kotak; Joan Korth-Bradley; Ron Pedersen; Linda Mele; Qi Shen; Bonnie Vlahos Journal: PLoS One Date: 2017-04-27 Impact factor: 3.240
Authors: Faye L Norby; Elsayed Z Soliman; Lin Y Chen; Lindsay G S Bengtson; Laura R Loehr; Sunil K Agarwal; Alvaro Alonso Journal: Circulation Date: 2016-08-23 Impact factor: 29.690